학술논문
426P A multicenter, randomized, double-blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg
Document Type
Abstract
Author
Source
In Annals of Oncology November 2020 31 Supplement 6:S1409-S1409
Subject
Language
ISSN
0923-7534